Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) FCF Margin (2018 - 2025)

Historic FCF Margin for Serina Therapeutics (SER) over the last 8 years, with Q2 2025 value amounting to 2941.54%.

  • Serina Therapeutics' FCF Margin rose 127623800.0% to 2941.54% in Q2 2025 from the same period last year, while for Sep 2025 it was 14288.79%, marking a year-over-year decrease of 138924000.0%. This contributed to the annual value of 30641.07% for FY2024, which is 305465600.0% down from last year.
  • Latest data reveals that Serina Therapeutics reported FCF Margin of 2941.54% as of Q2 2025, which was up 127623800.0% from 32814.29% recorded in Q4 2024.
  • In the past 5 years, Serina Therapeutics' FCF Margin registered a high of 32814.29% during Q4 2024, and its lowest value of 32720.0% during Q1 2022.
  • In the last 5 years, Serina Therapeutics' FCF Margin had a median value of 7850.0% in 2021 and averaged 9306.84%.
  • The largest annual percentage gain for Serina Therapeutics' FCF Margin in the last 5 years was 328126300bps (2024), contrasted with its biggest fall of -294566700bps (2024).
  • Quarter analysis of 5 years shows Serina Therapeutics' FCF Margin stood at 6100.0% in 2021, then crashed by -171bps to 16512.5% in 2022, then surged by 100bps to 1.65% in 2023, then skyrocketed by 1986129bps to 32814.29% in 2024, then tumbled by -109bps to 2941.54% in 2025.
  • Its FCF Margin was 2941.54% in Q2 2025, compared to 32814.29% in Q4 2024 and 21178.57% in Q3 2024.